Dexcom (DXCM) Accumulated Expenses (2010 - 2026)

Dexcom (DXCM) has 17 years of Accumulated Expenses data on file, last reported at $121.8 million in Q1 2026.

• Quarterly Accumulated Expenses rose 9.93% year-over-year to $121.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $121.8 million (up 9.93% YoY) and the FY2025 annual result came in at $169.2 million, up 51.07% from the prior year.
• Accumulated Expenses eased to $121.8 million in Q1 2026 per DXCM's latest filing, from $169.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $171.0 million in Q4 2023 and bottomed at $84.7 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $112.7 million (2022), against an average of $123.4 million.
• The widest annual swing landed in 2024, when Accumulated Expenses slumped 34.5%; it then jumped 60.87% in 2025.
• Tracing DXCM's Accumulated Expenses over 5 years: stood at $134.3 million in 2022, then rose by 27.33% to $171.0 million in 2023, then tumbled by 34.5% to $112.0 million in 2024, then surged by 51.07% to $169.2 million in 2025, then retreated by 28.01% to $121.8 million in 2026.
• Per Business Quant, the three latest DXCM Accumulated Expenses figures stand at $121.8 million (Q1 2026), $169.2 million (Q4 2025), and $170.2 million (Q3 2025).

Peer Comparison